Antimicrobial options in the treatment of adult staphylococcal bone and joint infections in an era of drug shortages

Orthopedics

Volumn 35, Issue 5, 2012, Pages 401-407

  Mruk, Allison L ^a   Record, Kenneth E ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEFALEXIN; CEFAZOLIN; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TIGECYCLINE; VANCOMYCIN;

ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; ARTICLE; BODY FLUID; BONE INFECTION; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; DEBRIDEMENT; DIARRHEA; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEMOLYTIC ANEMIA; HUMAN; HYPERKALEMIA; INFECTIOUS ARTHRITIS; INTERSTITIAL NEPHRITIS; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MYALGIA; MYOCLONUS SEIZURE; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOMYELITIS; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PROSTHESIS INFECTION; QT PROLONGATION; RED MAN SYNDROME; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; SURGICAL DRAINAGE; TENDINITIS; TENDON RUPTURE; THROMBOCYTOPENIA; TREATMENT INDICATION; VOMITING;

ANTI-BACTERIAL AGENTS; HUMANS; JOINTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 84861520387     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20120426-07     Document Type: Article

References (41)

1. Darley ESR, MacGowan AP. Antibiotic treatment of Gram-positive bone and bone infections [published online ahead of print April 20, 2004]. J Antimicrob Chemother. 2004; 53:928-935. (Pubitemid 38811422)
2. Que Y, Moreillon P. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:2543-2575.
3. McManus MC. Mechanisms of bacterial resistance to antimicrobial agents. Am J Health Syst Pharm. 1997;54(12):1420-1433. (Pubitemid 27260181)
4. Wielders CLC, Fluit AC, Brisse S, Verhoef J, Schmitz FJ. mecA gene is widely disseminated in Staphylococcus aureus population. J Clin Microbiol. 2002; 40(11):3970-3975. (Pubitemid 35285775)
5. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12(suppl 1):16-23.
6. Amsden GW, Ballow CH, Bertino JS, et al. Pharmacokinetics and pharmacodynamics of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:297-306.
7. Chambers HF. Beta-lactam & other cell wall & membrane-active antibiotics. In: Katzung BG, ed. Basic and Clinical Pharmacology. 10th ed. New York, NY: McGraw-Hill; 2007:726-741.
8. Chambers HF. Penicillins and β-lactam inhibitors. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:309-321.
9. Saravoltaz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011; 52(9):1156-1163.
10. Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:323-336.
11. Chambers HF. Carbapenems and monobactams. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:341-344.
12. Levin TP, Suh B, Axelrod P, et al. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother. 2005; 49(3):1222-1224. (Pubitemid 40327755)
13. Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:427-443.
14. Chambers HF. Tetracyclines, macrolides, clindamycin, chloramphenicol, & streptogramins. In: Katzung BG, ed. Basic and Clinical Pharmacology. 10th ed. New York, NY: McGraw-Hill; 2007:745-753.
15. Chambers HF. Sulfonamides, trimethoprim, & quinolones. In: Katzung BG, ed. Basic and Clinical Pharmacology. 10th ed. New York, NY: McGraw-Hill; 2007:763-769.
16. Hooper DC, Strahilevitz J. Quinolones. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:487-504.
17. Calfee DP. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:403-413.
18. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52:285-292.
19. Gold HS, Satish KP. Antistaphylococcal agents. Infect Dis Clin N Am. 2009; 23:99-131.
20. Zinner SH, Mayer KH. Sulfonamides and trimethoprim. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:475-482.
21. Salvatore M, Meyers BR. Tetracyclines and chloramphenicol. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:385-398.
22. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs. 2006; 66(8):1089-1105. (Pubitemid 43945869)
23. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis. 1994; 18:422-427. (Pubitemid 24086316)
24. American Academy of Orthopaedic Surgeons. Information: recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthoroplasty. http://www.aaos.org/about/papers/advistmt/1027.asp. Accessed February 2, 2012.
25. Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis [published online ahead of print June 8, 2010]. J Antimicrob Chemother. 2010; 65:1749-1752.
26. Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporin among patients allergic to penicillins. Clin Exp Allergy. 2001; 31:438-443. (Pubitemid 34204165)
27. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004; 364(9431):369-379.
28. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002; 346(5):334-339.
29. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults [published online ahead of print December 12, 2011]. Clin Infect Dis. 2012; 54(3):393-407.
30. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals [published online ahead of print June 28, 2005]. Clin Infect Dis. 2005; 41(4):435-440. (Pubitemid 41099634)
31. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004; 351:1645-1654.
32. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA. 1998; 279(19):1537-1541. (Pubitemid 28233008)
33. Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Hsueh PR. Emergency of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Am Geriatr Soc. 2010; 58(5):1001-1003.
34. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control. 2007; 35:106-114. (Pubitemid 46283602)
35. Murray BE, Nannini EC. Glycopeptides (vancomycin and teicoplanin), streptogramins (quinupristin-dalfopristin), and lipopeptides (daptomycin). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Vol 1. 7th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:449-465.
36. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007; 120(10 suppl 1):S13-S20. (Pubitemid 47464123)
37. Rice DAK, Mendez-Vigo L. Daptomycin in bone and joint infections: a review of the literature [published online ahead of print November 7, 2008]. Arch Orthop Trauma Surg. 2009; 129(11):1495-1504.
38. Aneziokoro CO, Cannon JP, Pachucki CT, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother. 2005; 17(6):643-650. (Pubitemid 43097752)
39. Sanchez GM, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010; 303:2260-2264.
40. U.S. Food and Drug Administration. Safety. Zyvox (linezolid). http://www.fda.gov/Safety/MedWatch/SafetyInformation/ afetyAlertsforHumanMedicalProducts/ucm152993.htm. Updated June 19, 2009. Accessed February 2, 2012.
41. Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg. 2009; 23(2):90-98.